XNAS · Healthcare · Biotechnology
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.19 | -0.20 | -5.26% | $0 | ❌ Miss | +0.00% | +7.42% | — |
| 2026-03-19 | Q4 2025 | -0.22 | -0.24 | -9.09% | $0 | ❌ Miss | -2.76% | +3.54% | +9.84% |
| 2025-11-05 |
| Q3 2025 |
| -0.22 |
| -0.21 |
| +4.55% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-28 | Q4 2024 | -0.19 | -0.25 | -31.58% | $0 | ❌ Miss | -12.34% | -22.40% | -5.84% |
| 2024-11-14 | Q3 2024 | -0.18 | -0.19 | -5.56% | $0 | ❌ Miss | -19.73% | -16.33% | -19.73% |
| 2024-08-14 | Q2 2024 | -0.24 | -0.22 | +8.33% | $0 | ✅ Beat | +1.91% | -1.91% | +16.75% |
| 2024-04-01 | Q4 2023 | -0.19 | -0.25 | -31.58% | $0 | ❌ Miss | +0.19% | -10.88% | -37.40% |
| 2023-11-14 | Q3 2023 | -0.18 | -0.20 | -11.11% | $0 | ❌ Miss | -7.61% | -28.86% | +1.51% |
Showing last 8 quarters.